Multiple Myeloma and Vitamin D3 as Therapy

Share Button

Vitamin D Levels Are Frequently below Normal in Multiple Myeloma Patients

According to the study linked and excerpted below, blood levels of vitamin D3 are an important predictor of multiple myeloma.

I began supplementing with Vitamin D3 years ago. Being a survivor a multiple myeloma (incurable blood cancer) I decided that I should take Vitamin D3 daily. I supplement with Life Extension Vitamin D3 (1000mg x 2 daily).

A collage of vitamin D including fish oil, salmon, and sunlight.

According to optimal blood levels of Vitamin D3 may prevent cancer, enhance bone health, reduce the risk of Parkinson’srheumatoid arthritis, heart attacks, diabetes, hypertension,  reduce symptoms of fibromyalgia, reduce the risk uterine fibroids,  Alzheimer’s disease, dementia, depression,  and other conditions.

  LEF Vitamin D3 is approved by for freshness and purity (you must be a member to access the report). Why do I supplement with LEF Vitamin D3?

  • Vitamin D3 is well-studied, well-researched for its many health benefits-
  • LEF Vitamin D3 is approved by Quality Certification Program
  • Cost-effective at .01 cents cost per 400 IU (.01 cents to .06 cost per 400 IU in evaluation range)
  • LEF Vitamin D3 is available through Amazon Prime–
  • 5% of your Amazon purchase will be donated to PeopleBeatingCancer to support cancer patients with research and education-

Thank you

David Emerson

  • Long-term  MM Survivor,
  • MM Cancer Coach
  • Director PeopleBeatingCancer

Recommended Reading:

Vitamin D Levels Are Frequently below Normal in Multiple Myeloma Patients and Are Infrequently Assessed By Their Treating Physicians

“Conclusion: Vitamin D levels are frequently low among multiple myeloma patients and, despite this, screening levels of this vitamin is not thought to be part of the routine work up by the vast majority of oncologists in the United States.”

Vitamin D Deficiencies Can Impact Myeloma Outcomes

“Most people do not think about their vitamin D intake, but Chloe Spear, BSN, RN, OCN, knows that it is important – especially for patients with myeloma.

Spear, clinical specialty coordinator in the Myeloma Program at Mount Sinai, conducted a study examining the effects that a vitamin D deficiency can have on outcomes for patients with myeloma. She hopes to turn her findings – that patients with deficiencies have poorer prognoses – into a standard-of-care for treating patients who come into the clinic with vitamin D deficiencies. Intervention would be fairly simple and straightforward: prescribing patients with oral vitamin D supplements to take daily.”

Leave a Comment:

Add Your Reply